Testim Patent Expiration

Testim is a drug owned by Endo Operations Ltd. It is protected by 10 US drug patents filed in 2013. Out of these, 1 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 18, 2025. Details of Testim's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320968 Pharmaceutical composition
Jan, 2025

(27 days from now)

Active
US7608608 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7608609 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US8063029 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7608607 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7608610 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7608605 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7935690 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US8178518 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired
US7608606 Pharmaceutical composition
Apr, 2023

(1 year, 8 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Testim's patents.

Given below is the list of recent legal activities going on the following patents of Testim.

Activity Date Patent Number
Patent litigations
Expire Patent 17 Jun, 2024 US8178518 (Litigated)
Maintenance Fee Reminder Mailed 01 Jan, 2024 US8178518 (Litigated)
Expire Patent 25 Dec, 2023 US8063029 (Litigated)
Maintenance Fee Reminder Mailed 10 Jul, 2023 US8063029 (Litigated)
Expire Patent 05 Jun, 2023 US7935690 (Litigated)
Maintenance Fee Reminder Mailed 19 Dec, 2022 US7935690 (Litigated)
Expire Patent 29 Nov, 2021 US7608606 (Litigated)
Expire Patent 29 Nov, 2021 US7608605 (Litigated)
Expire Patent 29 Nov, 2021 US7608607 (Litigated)
Expire Patent 29 Nov, 2021 US7608609 (Litigated)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Testim is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Testim's family patents as well as insights into ongoing legal events on those patents.

Testim's Family Patents

Testim has patent protection in a total of 29 countries. It's US patent count contributes only to 39.0% of its total global patent coverage. 17 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Testim.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Testim's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 18, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Testim Generic API suppliers:

Testosterone is the generic name for the brand Testim. 15 different companies have already filed for the generic of Testim, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Testim's generic

How can I launch a generic of Testim before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Testim's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Testim's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Testim -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.01 21 Aug, 2008 1 11 Jun, 2008 Extinguished

Alternative Brands for Testim

Testim which is used for testosterone replacement therapy., has several other brand drugs using the same active ingredient (Testosterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Acerus
Natesto
Alza
Testoderm
Testoderm Tts
Antares Pharma Inc
Xyosted (autoinjector)
Auxilium Pharms Llc
Striant
Azurity
Azmiro
Besins Hlthcare
Androgel
Eli Lilly And Co
Axiron
Endo Operations
Aveed
Fortesta
Marius Pharms Llc
Kyzatrex
Tolmar
Jatenzo
Upsher Smith Labs
Vogelxo
Verity
Tlando


Apart from brand drugs containing the same ingredient, some generics have also been filed for Testosterone, Testim's active ingredient. Check the complete list of approved generic manufacturers for Testim





About Testim

Testim is a drug owned by Endo Operations Ltd. It is used for testosterone replacement therapy. Testim uses Testosterone as an active ingredient. Testim was launched by Endo Operations in 2002.

Approval Date:

Testim was approved by FDA for market use on 31 October, 2002.

Active Ingredient:

Testim uses Testosterone as the active ingredient. Check out other Drugs and Companies using Testosterone ingredient

Treatment:

Testim is used for testosterone replacement therapy.

Dosage:

Testim is available in gel form for transdermal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG/5GM PACKET GEL Prescription TRANSDERMAL